Skip to main content

Month: January 2025

Genius Metals Changes Its Name to “Morocco Strategic Minerals Corporation”

MONTRÉAL, Jan. 29, 2025 (GLOBE NEWSWIRE) — Genius Metals Inc. (TSXV: GENI) (the “Company”) held its annual and special meeting of shareholders on January 16th, 2025 (the “Meeting”). The Company is pleased to announce that shareholders representing more than 99% of votes cast approved a special resolution authorizing the Company to amend its articles to change its name to “Morocco Strategic Minerals Corporation” and “Corporation de minéraux stratégiques du Maroc” as its French name. The common shares of the Company continue to trade on the TSX Venture Exchange (“TSXV”) under its existing trading symbol, GENI. The effective date of the name change will be January 31st, 2025 and the Company’s common shares will commence trading on the TSXV under the new name and under the trading...

Continue reading

Anfield Announces Completion of Verification Drilling, Plans for Updated Resource and Mine Permitting at Slick Rock

VANCOUVER, British Columbia, Jan. 29, 2025 (GLOBE NEWSWIRE) — Anfield Energy Inc. (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT: 0AD) (“Anfield” or the “Company”) is pleased to announce that it has completed a 14-hole, 14,100-foot rotary drill program at its Slick Rock uranium and vanadium project, located in San Miguel County, Colorado. Anfield will use the drill results to both upgrade its uranium and vanadium resource estimate for Slick Rock – as found in its existing PEA – and prepare mine designs for a large mine permit for the project. Corey Dias, Anfield’s CEO, commented: “We are very pleased to have completed our Slick Rock drill program as part of our plan to advance our Slick Rock project through the permitting stage and, ultimately, to production. Anfield will pursue a Plan of Operations and mine plan for Slick Rock in 2025....

Continue reading

Telos Corporation Selected as Prime Contractor for the U.S. Navy SeaPort Next Generation Contract

ASHBURN, Va., Jan. 29, 2025 (GLOBE NEWSWIRE) — Telos Corporation (NASDAQ: TLS), a leading provider of cyber, cloud and enterprise security solutions for the world’s most security-conscious organizations, today announced its on-ramp as a prime contractor to the U.S. Navy – SeaPort Next Generation (SeaPort NxG) multiple award, indefinite-delivery/indefinite-quantity (IDIQ) contract. SeaPort NxG serves the Navy Virtual SYSCOM Commanders, including NAVAIR, NAVFAC, NAVSEA, NAVSUP, NAVWAR and ONR, as well as the Military Sealift Command (MSC) and the United States Marine Corps (USMC). SeaPort NxG is the U.S. Navy’s integrated and mandatory approach to contracting for professional support services (PSS). As a prime contractor, Telos will be eligible to bid on task orders until 2028, at which time the Navy will perform a re-compete for...

Continue reading

HealthTab™ and Patients Know Best® Bring Pharmacy-Based Blood Test Results to Millions in UK

VANCOUVER, British Columbia, Jan. 29, 2025 (GLOBE NEWSWIRE) — Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) today announced its successful integration of HealthTab™ the Company’s cloud-connected, pharmacy-based platform for testing and health data management, with Patients Know Best (PKB), the UK’s leading patient personal health record (PHR). The new partnership enables a seamless connection between real-time diagnostic results from pharmacy point-of-care testing and PKB’s PHR platform, enhancing data accessibility for patients and healthcare providers alike. Supporting HealthTab’s pilot with North East London, an existing PKB customer, this collaboration marks a significant step forward in advancing the government’s shift to community based screening and a more preventative approach...

Continue reading

Blue Foundry Bancorp Reports Fourth Quarter and Year-End 2024 Results

RUTHERFORD, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) — Blue Foundry Bancorp (NASDAQ:BLFY) (the “Company”), the holding company for Blue Foundry Bank (the “Bank”), reported a net loss of $11.9 million, or $0.55 per diluted common share, for the year ended December 31, 2024 compared to a net loss of $7.4 million, or $0.31 per diluted common share for the year ended December 31, 2023. The Company reported a net loss of $2.7 million, or $0.13 per diluted common share, for the three months ended December 31, 2024 compared to a net loss of $4.0 million, or $0.19 per diluted common share for the three months ended September 30, 2024, and a net loss of $2.9 million, or $0.13 per diluted common share for the three months ended December 31, 2023. James D. Nesci, President and Chief Executive Officer, commented, “We are very pleased with both...

Continue reading

Hanover Bancorp, Inc. Reports 2024 Full Year And Fourth Quarter Results Highlighted by Fourth Quarter Robust Margin Expansion and Record Non-interest Income

Fourth Quarter Performance HighlightsNet Income: Net income for the quarter ended December 31, 2024 totaled $3.9 million or $0.52 per diluted share (including Series A preferred shares). Record Non-interest Income: The Company reported record non-interest income of $4.2 million for the quarter ended December 31, 2024, an increase of $0.2 million or 5.89% from the quarter ended September 30, 2024 and $0.9 million or 28.67% from the quarter ended December 31, 2023. Net Interest Income: Net interest income was $13.8 million for the quarter ended December 31, 2024, an increase of $0.7 million or 5.39% from the quarter ended September 30, 2024 and $1.1 million, or 9.08% from the quarter ended December 31, 2023. Net Interest Margin: The Company’s net interest margin during the quarter ended December 31, 2024 increased to 2.53% from 2.37% in...

Continue reading

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Thursday, February 6, 2025, at 10:00 am ET. Company management will also participate in one-on-one meetings during the conference, which will run from February 5-6, 2025, in New York, NY. To access the live webcast and archived recording of the event, visit the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the...

Continue reading

The Chefs’ Warehouse to Announce Fourth Quarter and Fiscal Year 2024 Results on February 12, 2025

RIDGEFIELD, Conn., Jan. 29, 2025 (GLOBE NEWSWIRE) — The Chefs’ Warehouse, Inc. (NASDAQ: CHEF) today announced that the Company intends to release its financial results for the fourth quarter and fiscal year ended December 27, 2024 before the opening of the stock market on Wednesday, February 12, 2025 and host a conference call at 8:30 a.m. ET on Wednesday, February 12, 2025 to review those results. The conference call will be webcast live from the Company’s investor relations website at http://investors.chefswarehouse.com/. An online archive of the webcast will be available on the Company’s investor relations website for 30 days. About The Chefs’ Warehouse The Chefs’ Warehouse, Inc. (http://www.chefswarehouse.com) is a premier distributor of specialty food products in the United States, the Middle East and Canada focused on serving...

Continue reading

Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference

PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at Guggenheim’s SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 10:30 a.m. ET in New York, NY. A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days. About Cabaletta BioCabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune...

Continue reading

ZJK Industrial Group Hosts Grand Year-End Celebration to Unite Employees and Stakeholders for a Glorious Future

Shenzhen, China, Jan. 29, 2025 (GLOBE NEWSWIRE) — ZJK Industrial Co. Ltd. (NASDAQ: ZJK) (“ZJK Industrial” or the “Company”), a high-tech precision parts and hardware manufacturer for artificial intelligence (AI) infrastructure and smart technologies, today announced that on January 11, 2025, it held a grand year-end celebration party on behalf of ZJK Industrial Group (“Group” or “ZJK Group”). Employees from all the Group’s subsidiaries—Shenzhen Zhongjinke Hardware Products Co., Ltd., Zhongke Precision Components (Guangdong) Co., Ltd., PSM-ZJK Fasteners (Shenzhen) Co., Ltd., and ZJK Vietnam Precision Components Company Limited—joined the event alongside distinguished guests, including shareholders, directors, and representatives from investors, auditing firms, law firms, and major banks. The celebration, held under the theme of...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.